Skip to content
Surf Wiki
Save to docs
general/rare-cancers

From Surf Wiki (app.surf) — the open knowledge base

Adamantinoma

Rare bone tumor in the lower leg

Adamantinoma

Rare bone tumor in the lower leg

FieldValue
nameAdamantinoma
imageAdamantinoma - intermed mag.jpg
captionMicrograph (using H&E stain) of an adamantinoma showing the biphasic histomorphology.

Adamantinoma () is a rare bone cancer, making up less than 1% of all bone cancers. It almost always occurs in the bones of the lower leg and involves both epithelial and osteofibrous tissue.

The condition was first described by Fischer in 1913.

Presentation

Patients typically present with swelling with or without pain. The slow-growing tumor predominantly arises in long bones in a subcortical location (95% in the tibia or fibula).

Benign osteofibrous dysplasia may be a precursor of adamantinoma or a regressive phase of adamantinoma.

Histologically, islands of epithelial cells are found in a fibrous stroma. The tumor is typically well-demarcated, osteolytic and eccentric, with cystic zones resembling soap bubbles.

Diagnosis

Radiograph showing an adamantinoma in the distal tibia with lytic expansive changes.

X-rays of the affected area show a well defined tumour in bone, with multiple lobules giving a "soap bubble" appearance. MRI can provide a more useful guide to its severity.

Treatment

Treatment consists of wide resection or amputation. Metastases are rare at presentation but may occur in up to 30% of patients during the disease course. Prognosis is excellent, with overall survival of 85% at 10 years, but is lower when wide surgical margins cannot be obtained. This tumor is insensitive to radiation so chemotherapy is not typically used unless the cancer has metastasized to the lungs or other organs.

History

The typically benign odontogenic tumor known as ameloblastoma was first recognized in 1827 by Cusack. Still, it did not yet have any designation. In 1885, this kind of odontogenic neoplasm was designated as an adamantinoma by Malassez. It was finally renamed to the modern name ameloblastoma in 1930 by Ivey and Churchill.

References

References

  1. Fischer B. Uber ein primares Adamantinom der Tibia. 12. Frankfurt: Zeitschr. f. Path.; 1913:422-441.
  2. (1994). "Relationship between osteofibrous dysplasia and adamantinoma.". Clin Orthop Relat Res.
  3. Gleason, Briana C.. (2008). "Osteofibrous Dysplasia and Adamantinoma in Children and Adolescents: A Clinicopathologic Reappraisal". American Journal of Surgical Pathology.
  4. (2020). "Soft Tissue and Bone Tumours: WHO Classification of Tumours". International Agency for Research on Cancer.
  5. (1930). "The need of a standardized surgical and pathological classification of tumors and anomalies of dental origin". Am Assoc Dent Sch Trans.
  6. (Jan 2006). "Giant ameloblastoma of jaw successfully treated by radiotherapy". Oral Oncology Extra.
  7. L. Malassez. (1885). "Sur Le role des debris epitheliaux papdentaires". Arch Physiol Norm Pathol.
  8. (May 2006). "A classic adamantinoma arising from osteofibrous dysplasia-like adamantinoma in the lower leg: a case report and review of the literature". Tohoku J. Exp. Med..
  9. (1995). "Neuro-ophthalmologic Aspects of Ameloblastoma". Skull Base Surg.
  10. (2008). "Adamantinoma: A clinicopathological review and update". Diagn Pathol.
  11. "Adamantinoma: Overview - eMedicine".
  12. Ernest U. Conrad. (2008). "Orthopaedic Oncology: Diagnosis and Treatment". Thieme.
Info: Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

Want to explore this topic further?

Ask Mako anything about Adamantinoma — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report